Surzetoclax
Sponsors
AbbVie Deutschland GmbH & Co. KG, AbbVie
Conditions
Multiple MyelomaMultiple Myeloma (MM)Multiple Myeloma (MM).
Phase 1
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RecruitingNCT06953960
Start: 2025-07-23End: 2030-12-01Target: 325Updated: 2026-09-11
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
RecruitingCTIS2024-517140-65-00
Start: 2025-10-23Target: 76Updated: 2025-12-08
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
Not yet recruitingCTIS2025-525105-20-00
Target: 76Updated: 2026-07-14